NASDAQ
200.98USD
-4.42 (-2.15%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
10.3B
P/E
—
EPS
—
Beta
0.60
52W range
112.9-260.19
Day range
200.20–209.53
Open
207.58
Prev close
205.40
Volume
260.3K
Avg volume
858.6K
Dividend
0.00
IPO
2015-11-19
https://www.marketbeat.com/instant-alerts/axsome-therapeutics-readies-auvelity-alzheimers-agitation-launch-expands-cns-pipeline-2026-06-05/ · 6/6/2026+0.90
https://www.zacks.com/stock/news/2915100/axsm-q1-loss-widens-revenues-jump-on-higher-auvelity-sales?cid=CS-STOCKNEWSAPI-FT-analyst_blog|earnings_article-2915100 · 5/5/2026+0.30
https://www.fxempire.com/forecasts/article/dow-jones-and-sp500-us-stocks-turn-cautious-as-crude-oil-volatility-1595578 · 5/4/2026-0.80
https://www.fool.com/investing/2026/05/02/why-axsome-therapeutics-stock-jumped-over-20-in-ap/ · 5/2/2026+1.00
https://www.defenseworld.net/2026/04/04/sg-americas-securities-llc-acquires-5584-shares-of-axsome-therapeutics-inc-axsm.html · 4/4/2026+0.60
https://www.defenseworld.net/2026/04/04/1900-wealth-management-llc-has-2-72-million-stake-in-tesla-inc-tsla.html · 4/4/2026+0.30
https://seekingalpha.com/article/4880791-axsome-therapeutics-inc-axsm-presents-at-leerink-global-healthcare-conference-2026-transcript · 3/10/2026+0.00
https://www.fool.com/investing/2026/03/10/2-under-the-radar-stocks-to-buy-and-hold/ · 3/10/2026+0.80
https://www.fool.com/investing/2026/02/03/1-high-flying-stock-with-more-upside-ahead/ · 2/3/2026+0.90
https://seekingalpha.com/article/4858926-moneyshow-best-investment-ideas-for-2026-part-2 · 1/12/2026+0.80
https://www.fool.com/investing/2025/12/31/why-axsome-therapeutics-stock-rocketed-higher-toda/ · 12/31/2025+1.00
https://www.globenewswire.com/news-release/2025/12/31/3211733/33090/en/Axsome-Therapeutics-Announces-FDA-Pre-NDA-Meeting-Minutes-for-AXS-12-in-Narcolepsy-Supporting-NDA-Submission.html · 12/31/2025+0.80
Axsome Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and advancing innovative treatments for a range of central nervous system (CNS) disorders within the United States. Its robust product pipeline features several promising candidates, including: AXS-05, an investigational therapy currently being developed for major depressive disorder and treatment-resistant depression. This compound is also in Phase III clinical evaluation for Alzheimer's disease agitation and has successfully finished Phase II trials investigating its use for smoking cessation. AXS-07, a novel, orally administered, rapidly-acting investigational medicine that employs multiple mechanisms of action. It has concluded two Phase III studies for the acute treatment of migraine attacks. AXS-12, a selective and potent norepinephrine reuptake inhibitor, which is presently undergoing a Phase III trial for narcolepsy. AXS-14, an oral investigational drug, advancing through Phase III trials for the management of fibromyalgia. Axsome Therapeutics also engages in a research collaboration with Duke University to further assess AXS-05's potential in smoking cessation. The company, established in 2012, has its main offices in New York, New York.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
